Get 50% OFF This Monsoon!
Aarey Drugs & Pharmaceuticals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Aarey Drugs & Pharmaceuticals Ltd is one of the manufacturer and suppliers of pharmaceutical raw materials, Chemicals, Pharmaceuticals ingredients, API's Drugs, Food Colours and Flavours. The company is engaged in the business of manufacturing, selling of drugs & pharmaceutical products and is governed by a number of central and state legislations that regulate the business. Apart from the bulk drug manufacturing activity, they also undertake importing & distributing of various industrial chemicals & solvents throughout the country. The company has their manufacturing unit located at Thane.
The company's products include Methyl Nitro Imidazole, Metronidazole & Metronidazole Benzoate. Their pharmaceutical products are sourced from the authentic vendors to assure the quality and effectiveness. The pharmaceutical products offered by the company are in compliance with IP/ BP/ CP/ USP standards. They have their registered office is located at Thane and their corporate office is located at Mumbai.
Aarey Drugs & Pharmaceuticals Ltd was originally incorporated on May 15, 1990 as a private limited company in Mumbai with the name Niharika Textiles & Chemicals Pvt Ltd. The company was originally promoted by Prakash Mandhana, Kavita Mandhana and Neeta Mandhana. The company was established with the main object setting up manufacturing facilities for Bulk Drugs.
In March 18, 1993, the Aarey Group of companies belonging to Ghatalia family took over the company and the company was converted into public limited company. Also, the name of the company was changed from Niharika Textiles & Chemicals Pvt Ltd to Aarey Drugs & Pharmaceuticals Ltd.
In the year 1993, the company came with a public issue of 27,50,000 equity shares of Rs 10 each for cash at par aggregating to Rs 275 lakh. Also, the company shares were listed on the BSE, ASE & DSE.
In May 2009, the company plant started to upgrade the existing plant into international standards.
The company plans to manufacture new products Sildenafil citrate, Tinidazole & Glyxol. They plan to expand the existing production capacity of Metronidazole (MTZ) from 420 MT to 780 MT (MTZ) and Metronidazole Benzoate (MBO) from 120 MT (MBO) to 240 MT (MBO).
Aarey Drugs & Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Aarey Drugs & Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Aarey Drugs & Pharmaceuticals is valued compared to its competitors.
Aarey Drugs & Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Aarey Drugs & Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Aarey Drugs & Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Aarey Drugs & Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Aarey Drugs & Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Aarey Drugs & Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Aarey Drugs & Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Aarey Drugs & Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Aarey Drugs & Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Aarey Drugs & Pharmaceuticals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Aarey Drugs & Pharmaceuticals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Aarey Drugs & Pharmaceuticals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Aarey Drugs & Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Aarey Drugs & Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Aarey Drugs & Pharmaceuticals .
The balance sheet presents a snapshot of Aarey Drugs & Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App